By Greg Brozeit | Posted - Nov 3rd, 2017





Myeloma Drug Candidate Gets Breakthrough Status

By: Greg Brozeit GlaxoSmithKline (GSK) announced that an antibody being developed to target BCMA in myeloma received the Food & Drug Administration’s (FDA) “Breakthrough Therapy Designation” on November 2, 2017. The new agent, GSK2857916, was granted similar status by the European Medicines Agency (EMA), the European Union’s counterpart to FDA, in October.  Both designations are based on phase 1 clinical trial data that will be presented on December 11 at the annual American Society of Hematology (ASH) meeting in Atlanta. The GSK therapy is currently being tested as a single agent in “treatment of relapsed and refractory multiple myeloma patients whose prior therapy included a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody.” A GSK spokesman announced that in addition being used as a single agent, the longer-term goal is to develop clinical trials “in combination with other approved therapies.” According to a law passed in 2012, the FDA may grant breakthrough status to any drug “intended…to treat a serious or life threatening disease” which “may demonstrate substantial improvement over existing therapies.” The Myeloma Crowd and SparkCures will publicize more information about the GSK drug candidate once the information when clinical trials are opened. BCMA is also one of the targets of CAR T cell research being funded by the Myeloma Crowd Research Initiative.

Greg Brozeit
About the Author

Greg Brozeit - Greg is the Program Director for the Myeloma Crowd patient education programs. He is based in Northeast Ohio.


Add a Comment



Thanks to our Myeloma Crowd Community sponsors:

.                         .